Guidelines on oral anticoagulation with warfarin - fourth edition - Wikidata - wikimedia - TriplyDB

Guidelines on oral anticoagulation with warfarin - fourth edition

Guidelines on oral anticoagulation with warfarin - fourth edition

http://www.wikidata.org/entity/Q28240666

about

How to manage warfarin therapy Managing atrial fibrillation in the very elderly patient: challenges and solutions Prevalence of Splanchnic Vein Thrombosis in Pancreatitis: A Systematic Review and Meta-Analysis of Observational Studies Takotsubo cardiomyopathy with left ventricular thrombus presenting as critical limb ischaemia.Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome Warfarin Pharmacogenetics: New Life for an Old Drug The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.Fluid overload is associated with increases in length of stay and hospital costs: pooled analysis of data from more than 600 US hospitals.Pregnancy outcomes in women with mechanical prosthetic heart valves: a prospective descriptive population based study using the United Kingdom Obstetric Surveillance System (UKOSS) data collection system.Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.Reversal of warfarin anticoagulation for urgent surgical procedures.Consensus guidelines for lumbar puncture in patients with neurological diseases.Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study.Pharmacogenetics of warfarin: challenges and opportunities.The clinical impact of different coagulometers on patient outcomes.Warfarin-induced deep vein thrombosis.Cerebrospinal fluid and lumbar puncture: a practical review.Utilization of oral anticoagulation in a teaching hospital in Nigeria Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE.Genotype and risk of major bleeding during warfarin treatment.Global assays and the management of oral anticoagulation.Lacunae in patient knowledge about oral anticoagulant treatment: results of a questionnaire survey.Factors driving anticoagulant selection in patients with atrial fibrillation in the United States.The state of point-of-care testing: a European perspective.Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.Benefits and risks of anticoagulation resumption following traumatic brain injury.Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.The Anticoagulation of Calf Thrombosis (ACT) project: study protocol for a randomized controlled trial.Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study Bilateral rectus sheath haematoma complicating dengue virus infection in a patient on warfarin for mechanical aortic valve replacement: a case report Service improvement system to enhance the safety of patients admitted on long-term warfarin.Warfarin Management Pathway: A clear and safe algorithm, from admission to discharge Factors influencing warfarin response in hospitalized patients.An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies Theoretical and practical issues related to the management of severe and refractory psychotic illness complicated by pulmonary embolism.Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial Tips for GP trainees working in haematology Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.

P2860

Q26773328-239C5454-5F5F-4600-8374-54FA28780D1E Q26775877-8DA39608-D02E-4C53-BC08-9E306CDC0CCA Q26785595-98B05395-611C-4B19-9CF9-C42CBB844315 Q27321719-C0BC4EA1-4D9F-49F9-8E4D-AA591376CFCB Q28067420-8BE90CDC-F3A8-451E-A7E7-616782CD13F8 Q28468726-FFDBDDFC-5E71-470E-B16B-5F25D2EFF2B3 Q28553937-BC47BF8A-2B3A-437E-84F6-F9B657653C56 Q30234372-D6F5D8EC-DD23-4770-9F8E-295A39AE514A Q30654191-15F0BF3E-67B5-4DF3-96A3-28D5F7CFD47B Q31151341-CEC97BA2-F897-4574-8C36-E6A0022AD34D Q33403703-01406016-F84C-4611-A9C1-C826E99D2B27 Q33421728-C636B6F8-8D50-46F4-926C-01A77E939C9F Q33753332-1971C981-A791-4BF2-9524-F34AF789D431 Q33771506-2545FC2A-DA02-456C-9947-4D3E8F5DC1E5 Q33819050-81AA5F25-9C2E-4877-981A-45958C3907C9 Q33848923-4CB24AB4-A6B4-465E-9F29-429AEE05F2BB Q34202081-45FC255F-DCCA-44C1-BC3A-8A4E25A224A5 Q34249708-531ED4B5-911C-49E4-BA4C-E9E27B605208 Q34418394-9082623B-E16F-44FD-8F74-B97B5BADF5CE Q34525565-636495F9-D200-44AC-9E1F-93BC775364C8 Q35006973-060F4D5E-1B6F-452D-BE83-5EF11106115A Q35164902-006D8BC4-414D-4146-904D-C72452879898 Q35220753-C32880CD-9BB8-4A43-84FE-1264F9CCF538 Q35235448-ADA16C5F-5392-47B0-BFB4-E9B7720CAE9A Q35308787-821E1CF8-863D-4CE5-8570-55855D8DCBBC Q35730774-7E973615-FD95-4C69-8EFA-9C5977278BDF Q35922778-DB1199B3-F5D2-4CC4-AB0E-8618C4C1AF7E Q35925359-3B1487F4-09BF-4541-B692-FD1B724A26F1 Q35972795-7223BB79-842E-441B-B41E-1072F806F8F3 Q36085794-D11DC41A-9370-4C01-BC46-A7699D7F41B6 Q36243413-8B812F63-9C20-4489-94E3-448F03A3281A Q36281952-51A8F8F5-7C25-40F2-A1A3-5EE577F5B17F Q36330599-0490E3E5-035A-4728-8916-870B7C3925DC Q36346124-68BF5D88-46D8-4639-A12D-BA0F1BD662BE Q36366940-B6ECA923-6AAE-40CD-9D7F-15C049F485B5 Q36458101-A2BBBEA4-A990-45B3-A083-0A2E11645CA0 Q36584522-5C1DBE28-416D-4CF3-9753-1FA46DDA97E6 Q36617893-A1B7C495-D4BE-4395-895C-07B3659E4F0D Q36870575-6B6D34E3-48F4-4343-B581-A92FEF6451F3 Q37018644-367C16B9-9ABF-4AB9-A43C-FDC9C4D334C0

P2860

Guidelines on oral anticoagulation with warfarin - fourth edition

http://www.wikidata.org/entity/Q28240666

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Guidelines on oral anticoagulation with warfarin - fourth edition

@ast

Guidelines on oral anticoagulation with warfarin - fourth edition

@en

Guidelines on oral anticoagulation with warfarin - fourth edition

@nl

type

label

Guidelines on oral anticoagulation with warfarin - fourth edition

@ast

Guidelines on oral anticoagulation with warfarin - fourth edition

@en

Guidelines on oral anticoagulation with warfarin - fourth edition

@nl

prefLabel

Guidelines on oral anticoagulation with warfarin - fourth edition

@ast

Guidelines on oral anticoagulation with warfarin - fourth edition

@en

Guidelines on oral anticoagulation with warfarin - fourth edition

@nl

P1433

Q28240666-2659809E-01CA-4B6E-9010-40A7F1D4D5B0

P1476

Q28240666-C7BDC468-8695-4E00-8767-C80CAA145864

P2093

Q28240666-56325F35-B162-4616-A225-646648867525

Q28240666-6BDDA923-BD8D-48E9-A876-FDECC38A910E

Q28240666-8B338FD2-7D0D-4D12-B8CD-DBDC7A00C6A5

Q28240666-9ABA9733-0583-405F-B1D9-CF38F64A7810

Q28240666-BBDC3FBB-5292-4BC5-AA2F-2089AADCF039

Q28240666-C6AE256D-FDF6-4D7D-ACED-5AF656667497

Q28240666-CC58AF83-248B-4139-A50A-EE560B7E6951

Q28240666-E1649579-CAB7-4853-A504-DFD610794F39

P2860

Q28240666-03485B11-E51D-42C1-989D-6A9EDB2DEC27

Q28240666-03B422E3-0332-4CDE-B9D3-B53A9AA520B0

Q28240666-03D5A82F-A887-4530-AFD8-BFAEBE48F1C7

Q28240666-05999F2B-E8A9-48DC-9BE4-82CBA3750BC1

Q28240666-06D14E4E-48E2-4A38-A64F-80E71E50EC79

Q28240666-07C1135D-1874-47B8-8242-558BD9CF2DF0

Q28240666-09326867-FD1C-41C7-BC53-EA84B524D02B

Q28240666-09F53257-E741-4B8A-AFB6-BA704B936A17

Q28240666-0C88FEC8-895E-44FE-812D-5525E8828E56

Q28240666-0CF570C3-4838-4F27-8228-A2718D6C3B61

P304

Q28240666-EAD8A921-4FD1-4973-B445-AE2BEB7A6CAD

P31

Q28240666-CC138DAB-4915-4C12-AC57-8D429C260281

P3181

Q28240666-688D00E1-805E-45BD-9BDF-FD4637B852AA

P356

Q28240666-68886BB2-D5A4-44C9-A484-9ABE75A2A074

P407

Q28240666-750AE37E-14E3-4E51-8597-8BDF4071B9BE

P433

Q28240666-E361B88D-9075-48CE-8B13-077EF586B84A

P478

Q28240666-5082CE28-422E-42F3-83FE-E5512723B07B

P577

Q28240666-78CC0D0C-6937-47D9-B0B2-DD94CF0F5A25

P5875

Q28240666-A696D25B-331B-44E0-989B-A12E1A47056A

P698

Q28240666-C8310C78-C124-419F-B560-98EE8F181C4E

P921

Q28240666-74D23F6E-BE2F-499C-86A2-4056CED7D257

P3181

P356

J.1365-2141.2011.08753.X

P1433

British Journal of Haematology

P1476

Guidelines on oral anticoagulation with warfarin - fourth edition

@en

P2093

Campbell Tait

http://www.w3.org/2001/XMLSchema#string

Caroline Baglin

http://www.w3.org/2001/XMLSchema#string

David Keeling

http://www.w3.org/2001/XMLSchema#string

David Perry

http://www.w3.org/2001/XMLSchema#string

Henry Watson

http://www.w3.org/2001/XMLSchema#string

Michael Makris

http://www.w3.org/2001/XMLSchema#string

Steve Kitchen

http://www.w3.org/2001/XMLSchema#string

Trevor Baglin

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Antiplatelet and anticoagulation for patients with prosthetic heart valves

Assessment, investigation, and early management of head injury: summary of NICE guidance

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

Warfarin, aspirin, or both after myocardial infarction

The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials

Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials

P304

311-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

894528

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/J.1365-2141.2011.08753.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

154

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51217942

http://www.w3.org/2001/XMLSchema#string

P698

21671894

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation